Brokerages Set Conatus Pharmaceuticals Inc (CNAT) Price Target at $8.67
Shares of Conatus Pharmaceuticals Inc (NASDAQ:CNAT) have earned an average rating of “Hold” from the seven brokerages that are presently covering the stock, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, two have given a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $8.50.
CNAT has been the topic of several recent research reports. ValuEngine downgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 11th. Stifel Nicolaus downgraded shares of Conatus Pharmaceuticals from a “buy” rating to a “hold” rating and set a $4.00 price target on the stock. in a report on Thursday, December 6th. Zacks Investment Research downgraded shares of Conatus Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, February 19th. Roth Capital reaffirmed a “buy” rating on shares of Conatus Pharmaceuticals in a report on Wednesday, February 13th. Finally, HC Wainwright reduced their price target on shares of Conatus Pharmaceuticals from $14.00 to $8.00 and set a “buy” rating on the stock in a report on Monday.
CNAT stock traded down $0.12 during trading on Friday, reaching $2.73. 15,720 shares of the company were exchanged, compared to its average volume of 714,264. The company has a market cap of $83.37 million, a P/E ratio of -4.63 and a beta of 3.36. Conatus Pharmaceuticals has a 52-week low of $1.15 and a 52-week high of $6.74.
Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC lifted its holdings in shares of Conatus Pharmaceuticals by 19.4% in the fourth quarter. Geode Capital Management LLC now owns 208,346 shares of the biotechnology company’s stock valued at $360,000 after purchasing an additional 33,827 shares in the last quarter. Sofinnova Investments Inc. lifted its holdings in shares of Conatus Pharmaceuticals by 18.4% in the fourth quarter. Sofinnova Investments Inc. now owns 638,197 shares of the biotechnology company’s stock valued at $1,104,000 after purchasing an additional 99,282 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in shares of Conatus Pharmaceuticals by 50.4% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 62,163 shares of the biotechnology company’s stock valued at $108,000 after buying an additional 20,826 shares during the last quarter. Two Sigma Investments LP raised its position in shares of Conatus Pharmaceuticals by 761.1% in the fourth quarter. Two Sigma Investments LP now owns 250,085 shares of the biotechnology company’s stock valued at $433,000 after buying an additional 221,044 shares during the last quarter. Finally, Creative Planning acquired a new position in shares of Conatus Pharmaceuticals in the fourth quarter valued at approximately $38,000. 27.41% of the stock is currently owned by institutional investors.
About Conatus Pharmaceuticals
Conatus Pharmaceuticals Inc, a biotechnology company, focuses on the development and commercialization of novel medicines for the treatment of liver diseases in the United States. Its product candidates include Emricasan, an orally active pan-caspase protease inhibitor that is in Phase IIb clinical trials for post-orthotopic liver transplant as a result of hepatitis C virus infection with sustained viral response; for patients with portal hypertension; for patients liver fibrosis caused by nonalcoholic steatohepatitis; and for liver function.
Featured Story: Bollinger Bands
Receive News & Ratings for Conatus Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conatus Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.